YU, KUO MING,游国明,游國明,CHOO, QUI-LIM,朱 桂林,FOK, MANSON,霍 文逊,霍 文遜,LAU, JOHNSON YIU-NAM,刘 耀南,劉 耀南,朱 桂林,霍 文逊,霍 文遜,刘 耀南,劉 耀南
申请号：
TW105106142
公开号：
TW201703793A
申请日:
2016.03.01
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20Kd or 40Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.本發明提供了組合物及方法，在其中重組的介白素-11係經聚乙二醇化以增進在血清中之半衰期，同時具有所需的治療活性且表現更少的副作用。最佳地，介白素-11為N端經截切之人類的或人化的介白素-11且具有20Kd或40Kd分支的聚乙二醇部分(特別是Y字形或梳子形)，該聚乙二醇部分與N端之胺基偶合。這樣的化合物之特徵在於顯著地增加在血清中之穩定性且維持生物活性，同時顯著地減少血漿擴張。
